The government today said demand notices worth up to Rs 2,328.53 crore were issued to pharma firms for drug overpricing between August 27, 1997 and January 31, 2011, out of which only Rs 207.86 crore has been realised.
"On detection of overcharging cases since inception of NPPA on August 27, 1997 and till January 31, 2011, NPPA has issued demand notices in 786 no of cases involving an amount of Rs 2,328.53 crore...," Minister of State for Chemicals and Fertilisers Srikant Kumar Jena said in a written reply in Lok Sabha.
This amount includes overcharging and interest for selling medicines at a price higher than the prices fixed under Drugs Price Control Order (DPCO) 1995, he added.
"Of this Rs 207.86 crore has been realised. Out of this, an amount of Rs 1,930.41 crore is under litigation and pending in various courts and Rs 33.72 crore is pending for recovery with collectors of various states," Jena added.
The National Pharmaceutical Pricing Authority (NPPA) initiates action of overcharging against the companies as per provisions of the DPCO' 1995 and the Essential Commodities Act, 1955.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
